Identifying patients at risk for microalbuminuria via interaction of the components of the metabolic syndrome: A cross-sectional analytic study

Clinical Journal of the American Society of Nephrology

Volumn 2, Issue 5, 2007, Pages 984-991

  Franciosi, Monica ^a   Pellegrini, Fabio ^a   Sacco, Michele ^a   De Berardis, Giorgia ^a   Rossi, Maria C E ^a   Strippoli, Giovanni F M ^a   Belfiglio, Maurizio ^a   Tognoni, Gianni ^a   Valentini, Miriam ^a   Nicolucci, Antonio ^a  

^a Consorzio Mario Negri Sud ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ALBUMINURIA; ARTICLE; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTOR;

AGED; ALBUMINURIA; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS;

EID: 34548859277     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01190307     Document Type: Article

References (34)

1. Greaves M, Malia RG, Goodfellow K, Mattock M, Stevens LK, Stephenson JM, Fuller JH: Fibrinogen and von Willebrand factor in IDDM: Relationships to lipid vascular risk factors, blood pressure, glycaemic control and urinary albumin excretion rate - The EURODIAB IDDM Complications Study. Diabetologia 40: 698-705, 1997
2. Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ: Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 340: 319- 323, 1992
3. Yudkin JS, Forrest RD, Jackson CA: Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet 2: 530-533, 1988
4. Mattock MB, Morrish NJ, Viberti G, Keen H, Fitzgerald AP, Jackson G: Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 41: 736-741, 1992
5. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J: Blood pressure and end-stage renal disease in men. N Engl J Med 334: 13-18, 1996
6. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J: End-stage renal disease in African-American and white men: 16-year MRFIT findings. JAMA 277: 1293-1298, 1997
7. Savage S, Estacio RO, Jeffers B, Schrier RW: Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM. Diabetes Care 19: 1243-1248, 1996
8. Ekstrand AV, Groop PH, Gronhagen-Riska C: Insulin resistance precedes microalbuminuria in patients with insulin-dependent diabetes mellitus. Nephrol Dial Transplant 13: 3079-3083, 1998
9. Fujikawa R, Okubo M, Egusa G, Kohno N: Insulin resistance precedes the appearance of albuminuria in non-diabetic subjects: 6 years follow-up study. Diabetes Res Clin Pract 53: 99-106, 2001
10. World Health Organization: Consultation. In: Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications, Geneva, World Health Organization, 1999, pp 37-39
11. Franciosi M, De Berardis G, Rossi MC, Sacco M, Belfiglio M, Pellegrini F, Tognoni G, Valentini M, Nicolucci A: Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: The IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study. Diabetes Care 28: 1187-1194, 2005
12. National Institutes of Health: Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Cholesterol in Adults (Adult Treatment Panel III). Executive Summary, Bethesda, National Heart, Lung, and Blood Institute, National Institutes of Health, 2001. NIH Publication No. 01-3670
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985
14. Nicolucci A, Carinci F, Ciampi A: Stratifying patients at risk of diabetic complications: An integrated look at clinical, socioeconomic, and care-related factors. SID-AMD Italian Study Group for the Implementation of the St. Vincent Declaration. Diabetes Care 21: 1439-1444, 1998
15. Ciampi A: Constructing prediction trees from data: The RECPAM approach. In: Proceedings from the Prague 1991 Summer School on Computational Aspects of Model Choice, Heidelberg, Physica-Verlag, 1992, pp 105-152
16. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J: The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 140: 167-174, 2004
17. Groop L, Ekstrand A, Forsblom C, Widen E, Groop PH, Teppo AM, Eriksson J: Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 36: 642-647, 1993
18. Niskanen L, Laakso M: Insulin resistance is related to albuminuria in patients with type II (non-insulin-dependent) diabetes mellitus. Metabolism 42: 1541-1545, 1993
19. Nosadini R, Solini A, Velussi M, Muollo B, Frigato F, Sambataro M, Cipollina MR, De Riva F, Brocco E, Crepaldi G: Impaired insulin-induced glucose uptake by extrahepatic tissue is hallmark of NIDDM patients who have or will develop hypertension and microalbuminuria. Diabetes 43: 491-499, 1994
20. Nielsen S, Schmitz O, Orskov H, Mogensen CE: Similar insulin sensitivity in NIDDM patients with normo- and microalbuminuria. Diabetes Care 18: 834-842, 1995
21. Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM: Microalbuminuria is associated with insulin resistance in nondiabetic subjects: The insulin resistance atherosclerosis study. Diabetes 47: 793-800, 1998
22. Verdecchia P, Reboldi GP: Hypertension and microalbuminuria: The new detrimental duo. Blood Press 13: 198-211, 2004
23. Wang XL, Lu JM, Pan CY, Tian H, Li CL: A comparison of urinary albumin excretion rate and microalbuminuria in various glucose tolerance subjects. Diabet Med 22: 332-335, 2005
24. Tonolo G, Ciccarese M, Brizzi P, Puddu L, Secchi G, Calvia P, Atzeni MM, Melis MG, Maioli M: Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 20: 1891-1895, 1997
25. Tonolo G, Melis MG, Formato M, Angius MF, Carboni A, Brizzi P, Ciccarese M, Cherchi GM, Maioli M: Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 30: 980-987, 2000
26. Lee TM, Su SF, Tsai CH: Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension 40: 67-73, 2002
27. Bianchi S, Bigazzi R, Caiazza A, Campese VM: A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41: 565-570, 2003
28. Danesh FR, Sadeghi MM, Amro N, Philips C, Zeng L, Lin S, Sahai A, Kanwar YS: 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: Implications for diabetic nephropathy. Proc Natl Acad Sci U S A 99: 8301-8305, 2002
29. Zeng L, Xu H, Chew TL, Chisholm R, Sadeghi MM, Kanwar YS, Danesh FR: Simvastatin modulates angiotensin II signaling pathway by preventing Rac1-mediated upregulation of p27. J Am Soc Nephrol 15: 1711-1720, 2004
30. Park JK, Muller DN, Mervaala EM, Dechend R, Fiebeler A, Schmidt F, Bieringer M, Schafer O, Lindschau C, Schneider W, Ganten D, Luft FC, Haller H: Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int 58: 1420-1430, 2000
31. O'Donnell MP, Kasiske BL, Kim Y, Schmitz PG, Keane WF: Lovastatin retards the progression of established glomerular disease in obese Zucker rats. Am J Kidney Dis 22: 83-89, 1993
32. Yoshimura A, Inui K, Nemoto T, Uda S, Sugenoya Y, Watanabe S, Yokota N, Taira T, Iwasaki S, Ideura T: Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesangial proliferative nephritis. J Am Soc Nephrol 9: 2027-2039, 1998
33. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Pagano G, Cavallo Perin P; Casale Monferrato Study: Progression to overt nephropathy in type 2 diabetes: The Casale Monferrato Study. Diabetes Care 26: 2150-2155, 2003
34. Klein RL, Hunter SJ, Jenkins AJ, Zheng D, Semler AJ, Clore J, Garvey WT: DCCT/ECIC Study Group: Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: Studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort. Diabetes Care 26: 1439-1448, 2003